Back to search

Peptide record

TPDB06851

LfcinB Antibacterial Anticancer Antihypertensive Antiviral Cell-penetrating Peptides standard

12 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB06851

Peptide_Name

LfcinB

Activity

Antibacterial Anticancer Antihypertensive Antiviral Cell-penetrating Peptides

Activity_category_statistics

Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Delivery and barrier-penetrating peptides

Database_Source

AntiBP3 pep-lab Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AI4AVP CPPsite3.0

Sequence_Type

standard

Has_Modification No

Description A 12-aa standard natural multi-activity (Antibacterial, Anticancer, Antihypertensive, and other sources) peptide sequence curated from AntiBP3, pep-lab, Peptipedia, and other sources, with an available 3D structural model.

Sequence

FKCRRWQWRMKK

FASTA

>TPDB06851|Antibacterial;Anticancer;Antihypertensive;Antiviral;Cell-penetrating Peptides|length=12
FKCRRWQWRMKK

Formula C80H125N27O14S2

Absent Amino Acids ANDEGHILPSTYV

Common Amino Acids RK

Mass 1753.17

PI 12.14

Basic Residues 6

Acidic Residues 0

Hydrophobic Residues 4

Net Charge +6

Boman Index 0.68

Hydrophobicity -1.942

Aliphatic Index 0.00

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 11000

Absorbance 280nm 627.44

Polar Residues 2

number

Amino Acid Distribution

A: 0 R: 3 N: 0 D: 0 C: 1 E: 0 Q: 1 G: 0 H: 0 I: 0 L: 0 K: 3 M: 1 F: 1 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0

Length

Formula

C80H125N27O14S2

Mass

1753.17

12.14

Net Charge

Boman Index

0.68

Hydrophobicity

-1.942

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer Antimicrobial and Anticancer

Origin

Bovine lactoferrin (Lf-B)

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =40±7 µM

Detail Source Activity Anticancer

Activity Measurement 40

Target

Cancer Type Skin Cancer

Cell Line FEMX

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =148±8 µM

Detail Source Activity Anticancer

Activity Measurement 148

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 38 µM

Detail Source Activity Anticancer

Activity Measurement 38 µM

Target

Cancer Type Skin Cancer

Cell Line KMS-5

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 55 µM

Detail Source Activity Anticancer

Activity Measurement 55 µM

Target

Cancer Type Lymphoma Cancer

Cell Line U-266

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 57 µM

Detail Source Activity Anticancer

Activity Measurement 57 µM

Target

Cancer Type Skin Cancer

Cell Line KMM-1

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 16 µM

Detail Source Activity Anticancer

Activity Measurement 16 µM

Target

Cancer Type Skin Cancer

Cell Line Sudhl-4

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13 µM

Detail Source Activity Anticancer

Activity Measurement 13 µM

Target

Cancer Type Lymphoma Cancer

Cell Line Raji

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Lymphoma Cancer

Cell Line Ramos

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2009

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 > 160 µM

Detail Source Activity Anticancer

Activity Measurement 160 µM

Target

Cancer Type Colon Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 > 160 µM

Detail Source Activity Anticancer

Activity Measurement 160 µM

Target

Cancer Type Breast Cancer

Cell Line MT-1

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 11 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =141 ± 3 µM

Detail Source Activity Anticancer

Activity Measurement 141

Target

Cancer Type Brain Tumor

Cell Line Kelly

Tissue Affected Brain

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011